Before you view the webinar, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

There is no fee to participate in this activity.

Question Title

* 1. Where are you in your career?

Question Title

* 2. The addition of which of the following to an anti-TNF agent is associated with a higher rate of CPF healing vs the anti-TNF agent alone?

Question Title

* 3. A 25-year-old male with a recent diagnosis of CD presents with extreme perianal pain. A pelvic MRI is performed, leading to a diagnosis of CPF and abscess. Drainage of abscess and An examination under anesthesia is performed, during which a seton is placed in an intersphincteric fistula. The patient asks what to expect regarding his future course of therapy. 

Which of the following is an appropriate response?

Question Title

* 4. A 42-year-old female with refractory CPF asks about the possibility of receiving mesenchymal stem cell (MSC) therapy on a clinical trial. What do you tell the patient is an important education point regarding MSCs?

Question Title

* 5. According to the 2022 proposed new Expert Consensus (published in The Lancet Gastroenterology & Hepatology, linked here), refractory CPF despite ostomy requiring proctectomy is considered which class?

Question Title

* 6. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).
*Please note that we will not forward or sell your contact information.*

T